Related Experiment Videos
Intrapleural BCG in operable lung cancer
Lancet (London, England)
|January 5, 1980
Summary
Intrapleural bacillus Calmette-Guérin (BCG) did not significantly improve survival in patients after lung cancer surgery. The treatment showed minimal adverse effects in this clinical trial.
Area of Science:
- Oncology
- Immunotherapy
- Thoracic Surgery
Background:
- Lung cancer remains a leading cause of cancer mortality worldwide.
- Adjuvant therapies are crucial for improving outcomes after surgical resection.
- Intrapleural bacillus Calmette-Guérin (BCG) is investigated as an immunotherapy option.
Purpose of the Study:
- To evaluate the efficacy of intrapleural BCG in improving survival after lung cancer resection.
- To assess the safety and tolerability of intrapleural BCG in this patient population.
Main Methods:
- A controlled randomized clinical trial was conducted.
- 92 patients with surgically resected lung cancer were enrolled.
- Patients received intrapleural BCG as an adjuvant therapy.
Main Results:
- Intrapleural BCG demonstrated no clear beneficial effect on patient survival.
- The incidence of adverse effects associated with intrapleural BCG was insignificant.
Conclusions:
- Intrapleural BCG does not appear to be an effective adjuvant treatment for improving survival in patients with surgically resected lung cancer.
- The treatment is well-tolerated with minimal adverse events.